Skip to content
Subscriber Only

Glaxo Resumes Payments to Doctors That Were Halted After U.S. Probe

  • New policy will improve understanding of drugs, Glaxo says
  • Drugmaker in 2013 said it would end fees for physicians
GlaxoSmithKline Plc headquarters in London, U.K.

GlaxoSmithKline Plc headquarters in London, U.K.

Photographer: Matthew Lloyd/Bloomberg

Updated on

GlaxoSmithKline Plc will resume paying doctors to promote its medicines and attend medical meetings, reversing a policy introduced five years ago after a U.S. probe of its marketing and sales practices.

Glaxo’s approach in recent years has limited understanding of its products and ultimately restricted patients’ access to new drugs and vaccines, and hasn’t been followed by pharma rivals, the London-based company said Tuesday in a statement on its website. The policy applies only to certain products and markets, the company said.